The Man Van Project

Background Early intervention is potentially lifesaving for a range of conditions. A key cause of death from cancer and other causes is late presentation and there are key barriers to early access such as low education levels, difficult access to primary care (for example due to anti-social working hours) as well as lack of knowledge of relevant symptoms that might trigger referral and investigation. The Man Van project seeks to address some of these reasons for late presentation and started with an initial focus on prostate cancer. The project has now broadened to include a range of conditions that are major causes of mortality and morbidity in men such as heart and liver disease, other urological cancers (penile, testicular, bladder, kidney). The Man Van clinics will be focused on populations at risk of delayed presentation to healthcare systems such as men in manual or low skill jobs and workplaces with high numbers of black and ethnic minority employees. Prostate cancer is the most common cancer in men in the United Kingdom (UK), with over 50,000 new cases diagnosed and 15,000 lives lost to prostate cancer in the UK each year 1. This is of particular concern for black African and African Caribbean men who carry a 1 in 4 risk of developing prostate cancer, and for men with a family history of the disease. Another challenge is that, typically, men tend to approach their GP for men's health issues when symptoms are severe. Around 20-25% of men with prostate cancer still present to A\&E with retention. At this late-stage treatment is less likely to be successful and certainly will carry more morbidity for the patient and cost for the health care system. The recent COVID-19 pandemic has further exacerbated this issue with routine referrals to cancer diagnostics clinics dropping by around a third (in house data, Royal Marsden Hospital), suggesting a growing reservoir of un-diagnosed cancer in the community. Till date there is no consensus on the modality of prostate cancer screening, but most studies have focussed on PSA as a screening tool, with MRI scanning and biopsies as adjuncts to this. PSA itself has a controversial history in screening for prostate cancer with studies showing differing results. A key issue in using PSA as a screening tool comes from the definition of what a 'normal' PSA is. PSA increases with age and with benign growth of the prostate but can also be elevated in urinary tract infections or prostatic inflammation. Oesterling's age specific PSA ranges from 1993 are still in use today. Prostate cancer is of course another cause of PSA elevation. Having a higher PSA threshold for investigation increases the positive predictive value for detecting prostate cancer but lowers the negative predictive value, and the reverse is true as well. A study by Gerstenbluth documented a positive predictive value of 98.5% for PSA in detecting prostate cancer with a PSA of 50ng/ml or above. The evidence for screening is also controversial resulting in differing guidance around the world. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial from the USA looked at systematic vs opportunistic screening in over 76000 men. Using a PSA threshold of over 4 and 7-10 years of follow-up no significant difference in mortality from prostate cancer was found between the screened and non-screened arms. However, the study had high rates of contamination between the two groups with an estimated 74% of the control group subject to at least one routine PSA test during the trial (95% in the intervention arm) and around 50% of men in the control group tested each year. The European Randomized Study of Screening for Prostate Cancer (ERSPC) has been studying 186,000 men aged 55 to 69 in Europe since 1992. Now in its 16th year of follow-up6 results show a 20% reduction in cancer specific survival, and the numbers needed to treat was now below that which is observed in breast cancer strengthening the argument for some form of screening. A total of seven studies in different regions of Europe were included, with each study utilising different screening criteria and treatment protocols, interval timing, and PSA cut-offs (between 3 and 4), again muddying the waters. As a result of this conflicting evidence the National Institute of Clinical Excellence (NICE) guidelines suggest a risk stratified approach along with patient counselling. The guidelines recommend giving a PSA test to any man over the age of 50 years who requests it as well as offering it to men with lower urinary tract symptoms, haematuria, erectile dysfunction or symptoms that may suggest advanced prostate cancer such as unexplained bone pain or weight loss. However, routine systematic screening is not recommended. Rationale The rationale behind the introduction of the Man Van mobile outreach service is to increase patient access and support to cancer investigation pathways. This is particularly important in patient groups from lower socio-economic and high risk groups where delay in early intervention can result in delayed presentation and adverse health outcomes. We hope to demonstrate the feasibility and applicability of such a service to improve patient outcomes and hope to gather important qualitative and DNA based data for further research. This research project will analyse the clinical data obtained from each patient's routine health screening and long-term follow-up data from NHS Digital and other healthcare providers, to make a full assessment of how effective the Man Van mobile outreach model is in diagnosing prostate and other male cancers by making a comparison with the current detection rates from diagnoses made under the traditional screening and diagnosis pathway. It is anticipated that the results of this study will provide further evidence for the commissioning of targeted outreach programmes for early detection of prostate and other male cancers. Point of care testing (MV-POCT) Point of care blood testing is a feature of the van that will allow instant results to be given to patients, preventing the need for follow-up appointments and speeding up diagnoses. Both PSA and HbA1c tests are currently carried out on the van using formal laboratory blood tests which are then sent via courier to the Royal Marsden biochemical laboratory. As well as a formal laboratory validation process which is required before any point of care machine can be used (which is not part of the research protocol) we will determine what effect the difference between laboratory and point of care testing may have on the decision making process for patients. The clinical decision making from PSA testing will be whether an onwards referral for prostate cancer investigation is recommended by the clinical team. For HbA1c it will be whether a primary care referral for diabetic management is recommended by the clinical team. The laboratory value will be taken as the 'true' value in this instance as all final clinical decision making based on this. Qualitative questionnaire (MV-QualQ) As the Man Van provides a new clinical model for assessing patients, the patients' perspective on the model, and comparisons to existing clinical services is important. Going into more detail than a service evaluation questionnaire, a qualitative study has been developed to better understand how patients feel about and react to the service. A qualitative questionnaire has been developed following discussion group input via a modified Delphi process. The Delphi method is a commonly used method for achieving a consensus of opinion of real world knowledge from experts in the field. It was developed by Dalkey and Helmer at the Rand Corporation in the 1950s and is aimed at problem-solving, idea-generation, or determining priorities. The complexity of issues that prevent men from seeking or finding healthcare and our lack of understanding is the key driver for this study. This is particularly relevant for men from ethnic minorities and lower socio-economic groups. Understanding the barriers and facilitators to healthcare access may provide further support of the Man Van project and may help develop further research themes aimed at increasing healthcare access. In-depth qualitative patient interviews will be carried out on at least 5 patients to further delineate themes which arise from the questionnaires. With permission interviews will be recorded and transcribed to aid thematic analysis. Health Economic Analysis (MV-Eco) A key element of the Man Van project is its long-term use as a novel method of targeted screening and improving health care outcomes. Like all NHS funded services a cost-benefit analysis is integral to supporting the case for this project into the future. Health economic arguments form key parts of discussion for NICE and NHS England commissioning groups. The health economic arguments for prostate cancer screening remain unclear as they do for various diseases, however a combined approach that targets high risk patients and assess for prostate cancer, bladder/renal cancer, diabetes, hypertension and other diseases assessed for in the Man Van may make for a stronger economic argument. Polygenic risk scores (MV-PRS) Prostate cancer is the commonest cancer in men in the Western world, with over 40,000 new cases per annum. However, its aetiology remains very poorly understood. The substantial variation in incidence rates worldwide suggests that lifestyle risk factors are important however, no definite lifestyle risk factors have been identified till date. Family history has been identified as a significant risk factor for prostate cancer, as it is in many other cancers and diseases. Although this is likely due to inherited genetic pre-disposition, causation is yet to be fully established. Although gene mutations have been discovered as being causative factors for many diseases PRS allow for the amalgamation of greater variants in order to explain a larger proportion of diseases rather than single low penetrance variants. PRS has the potential to enhance risk susceptibility to a greater proportion of the population and offer new avenues in patient screening and disease prevention. The clinical application of PRS is subject of intense debate and ongoing research. We hope to add to this area of ongoing study, in particular with the combination of offering lifestyle modification advice in the context of PRS. PRS scores will be generated from saliva samples of DNA. As is common with many studies the under recruitment and under representation of ethnic minority patients remains an issue, resulting in less representative polygenic risk scores for patients of non-white ethnicities. We hope to address this via the Man Van by recruiting higher proportions of other ethnicities. DNA Collection (MV-DNA) Genetic studies have become a key part of cancer research, both for early diagnosis and prognostic reasons. A key issue for studies is trial recruitment, with significant issues in the recruitment of ethnic minorities to trials, which is particularly relevant when a disease may affect a particular ethnicity more (for example prostate cancer in Black men). DNA collection with either blood or saliva samples can help to build a database which can be used for further genetic studies. Urinary Circulating Tumour DNA collection (MV-UctDNA) Despite much research into the development of novel urinary biomarkers for bladder cancer, the mainstay of diagnosis remains invasive with a flexible (or rigid) cystoscopy. Even cystoscopy is only carried out after a red flag symptom triggers a referral (haematuria or recurrent infections). Several tests exist but none has replaced cystoscopy as the gold standard either for diagnosis of new bladder cancer or disease recurrence. Circulating tumour DNA (ctDNA) from urine has potential as a new avenue of development of diagnostic tests for bladder cancer and also prostate cancer.